Skip to main content

Conventional Treatment of Pancreatic Cancer

  • Conference paper
Standards in Pancreatic Surgery

Abstract

Carcinoma of the pancreas is the fourth leading cause of cancer death in the Western world [1]. Diabetes mellitus, high-fat diets, and tobacco smoking have been implicated as predisposing factors [2]. Ethanol consumption and pancreatitis may also be risk factors [2]. The 1-year overall survival rate in patients with pancreatic cancer is only 12% [3]. Three observations suggest that this malignancy will be an even more serious problem in the industrialized countries than it is today: (a) the incidence of pancreatic cancer increases dramatically after the fifth decade of life, and the general population in these countries is aging; (b) the incidence of diabetes in this population is increasing, and advances in the care of diabetic patients have led to an increase in their longevity; (c) the consumption of fat, alcohol, and tobacco is not abating. In view of the high mortality rate in patients with pancreatic cancer, there is an urgent need to improve the therapeutic options that are available for treating this disorder.

This study was supported by Public Health Service Grant CA-40162, awarded by the National Cancer Institute

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 119.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 159.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Similar content being viewed by others

References

  1. Wills JA (1989) Current status of chemotherapy in metastatic pancreatic cancer. Anticancer Res 9:1027–1032

    Google Scholar 

  2. Cubilla AL, Fitzgerald PJ (1985) Cancer of the exocrine pancreas: the pathological aspects. CA 35:2–35

    PubMed  CAS  Google Scholar 

  3. Gudjonsson B, Livstone E, Spiro H (1978) Cancer of the pancreas: diagnostic accuracy and survival studies. Cancer 42:2494–2506

    Article  PubMed  CAS  Google Scholar 

  4. Tepper J, Nardi G, Suite H (1976) Carcinoma of the pancreas: review of MGH experience from 1963–1973. Cancer 37:1519–1524

    Article  PubMed  CAS  Google Scholar 

  5. Levine G, Remine WH, Hermann RE, Schein PS, Cohn I (1978) Cancer of the pancreas. Am J Surg 135:185–191

    Article  Google Scholar 

  6. Almoguera C, Shibata D, Forrester K, Martin J, Arnheim N, Perucho M (1988) Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell 53:549–554

    Article  PubMed  CAS  Google Scholar 

  7. Korc M, Meltzer P, Trent J (1986) Enhanced expression of epidermal growth factor receptor correlates with alterations of chromosome 7 in human pancreatic cancer. Proc Natl Acad Sci USA 83:5141–5144

    Article  PubMed  CAS  Google Scholar 

  8. Smith JJ, Derynck R, Korc M (1987) Production of transforming growth factor a in human pancreatic cancer cells: evidence for a superagonist autocrine cycle. Proc Natl Acad Sci USA 84:7567–7570

    Article  PubMed  CAS  Google Scholar 

  9. Ohmura E, Okada M, Onoda N, Kamiya Y, Murakami H, Tsushima T, Shizume K (1990) Insulin-like growth factor I and transforming growth factor d as autocrine growth factors in human pancreatic cancer cell growth. Cancer Res 50:103–107

    PubMed  CAS  Google Scholar 

  10. Beauchamp RD, Lyons RM, Yang EY, Coffey RJ Jr, Moses HL (1990) Expression of and response to growth regulatory peptides by two human pancreatic carcinoma cell lines. Pancreas 5:369–380

    Article  PubMed  CAS  Google Scholar 

  11. Moriai T, Takebe T, Makino I, Ishii K (1989) Intratumoral treatment of pancreatic cancer with mitomycin-C adsorbed to activated carbon particles. Anticancer Res 9:1799–1804

    PubMed  CAS  Google Scholar 

  12. Smith FP, Hoth DF, Levin BL et al. (1980) 5-Fluorouracil, Adriamycin and mitomycin-C (FAM) chemotherapy for advanced adenocarcinoma of the pancreas. Cancer 46:2014

    Article  PubMed  CAS  Google Scholar 

  13. Moertel CG, Rubin J, O’Connell MJ et al. (1986) A phase II study of combined 5-fluorouracil, doxorubicin and cisplatin in the treatment of advanced upper gastrointestinal adenocarcinoma. J Clin Oncol 4:1053

    PubMed  CAS  Google Scholar 

  14. Pousetta A, Fernstad R, Haggmark A, Skoldefors H, Theve NO, Carlstrom K (1988) The estrogen binding protein in human pancreas: concentrations in subcellular fractions of normal pancreatic tissue, in duodenal juice during pancreatic stimulation and in peripheral serum in normal and pathological conditions. J Steroid Biochem 29:423–427

    Article  Google Scholar 

  15. Bakkevold KE, Pettersen A, Arnesjo B, Espehaug B (1990) Tamoxifen therapy in unresectable adenocarcinoma of the pancreas and the papilla of Vater. Br J Surg 77:725–730

    Article  PubMed  CAS  Google Scholar 

  16. Klijn JGM, Hoff AM, Planting ASTh, Verweij J, Kok T, Lamberts SWJ, portengen H, Foekens J A (1990) Treatment of patients with metastatic pancreatic and gastrointestinal tumours with the somatostatin analogue Sandostatin: a phase II study including endocrine effects. Br J Cancer 62:627–630

    Article  PubMed  CAS  Google Scholar 

  17. The Gastrointestinal Tumor Study Group (1981) Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil. Cancer 48:1705–1710

    Article  Google Scholar 

  18. Ozaki H, Hojo K, Kato H, Kinoshita T, Egawa S, Kishi K (1988) Multidisciplinary treatment for resectable pancreatic cancer. Int J Pancreatol 3:249–260

    PubMed  CAS  Google Scholar 

  19. Colacchio TA, Coughlin C, Taylor J, Douple E, Ryan T, Crichlow RW (1990) Intraoperative radiation therapy and hyperthermia. Arch Surg 125:370–375

    PubMed  CAS  Google Scholar 

  20. Raitano AB, Scuderi P, Korc M (1990) Binding and biological effects of tumor necrosis factor and gamma interferon in human pancreatic carcinoma cells. Pancreas 5:267–277

    Article  PubMed  CAS  Google Scholar 

  21. Schmiegel WH, Caeser J, Kalthoff H, Greten H, Schreiber HW, Thiele HG (1988) Antiproliferative effects exerted by recombinant tumor necrosis factor-α (rTNF-α) and interferon-γ (rlFN-γ) on human pancreatic tumor cell lines. Pancreas 3:180–188

    Article  PubMed  CAS  Google Scholar 

  22. Marincola FM, Da Pozzo LF, Drucker BJ, Holder WD Jr (1990) Adoptive immunotherapy of human pancreatic cancer with lymphokine-activated killer cells and interleukin-2 in a nude mouse model. Surgery 108:919–929

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 1993 Springer-Verlag Berlin Heidelberg

About this paper

Cite this paper

Korc, M. (1993). Conventional Treatment of Pancreatic Cancer. In: Beger, H.G., Büchler, M., Malfertheiner, P. (eds) Standards in Pancreatic Surgery. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-77437-9_65

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-77437-9_65

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-77439-3

  • Online ISBN: 978-3-642-77437-9

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics